同和药业取得发明专利证书，涉及产品替格瑞洛

Core Viewpoint - Tonghua Pharmaceutical has recently received an invention patent certificate from the National Intellectual Property Administration for a compound and its preparation method, which is related to the production of the intermediate for Ticagrelor, a novel antithrombotic drug [1] Group 1: Patent Announcement - The patent pertains to a class of compounds known as dioxolane compounds and their preparation methods [1] - The invention is specifically aimed at the preparation method for the intermediate of Ticagrelor [1] Group 2: Product Information - Ticagrelor is a new type of selective small-molecule anticoagulant that can block platelet activation [1] - It is used for treating patients with acute coronary syndrome, reducing the occurrence of thrombotic cardiovascular diseases, and is characterized by its rapid and potent effects [1]